Press release Biocartis Group NV: Mandatory Conversion Bondholder Notification
05 déc. 2022 11h40 HE | Biocartis NV
PRESS RELEASE: REGULATED INFORMATION5 December 2022, 17:40 CET Mandatory Conversion Bondholder Notification Capitalised terms not otherwise defined in this notice shall have the meaning given to...
Persbericht Biocartis Group NV: Kennisgeving van Verplichte Conversie aan de Obligatiehouders
05 déc. 2022 11h40 HE | Biocartis NV
PERSBERICHT: GEREGLEMENTEERDE INFORMATIE5 december 2022, 17:40 CET Kennisgeving van Verplichte Conversie aan de Obligatiehouders Bepalingen met een hoofdletter in deze kennisgeving die niet werden...
NOVARTIS logo.jpg
Novartis Pluvicto™ shows statistically significant and clinically meaningful radiographic progression-free survival benefit in patients with PSMA–positive metastatic castration-resistant prostate cancer
05 déc. 2022 01h15 HE | Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR Phase III PSMAfore trial with PluvictoTM met the primary endpoint of radiographic progression-free survival (rPFS) in PSMA–positive mCRPC who have been...
Press release Biocartis Group NV: Disclosure of a transparency notification
02 déc. 2022 11h45 HE | Biocartis NV
PRESS RELEASE: REGULATED INFORMATION                                                                                2 December 2022, 17:45 CET Disclosure of a transparency notification Mechelen,...
Persbericht Biocartis Group NV: Openbaarmaking van een transparantiekennisgeving
02 déc. 2022 11h45 HE | Biocartis NV
PERSBERICHT: GEREGLEMENTEERDE INFORMATIE2 december 2022, 17:45 CET         Openbaarmaking van een transparantiekennisgeving Mechelen, België, 2 december 2022 – Biocartis Group NV (de ‘Vennootschap’...
Press release Biocartis Group NV: Disclosure of Outstanding Voting Securities
02 déc. 2022 11h40 HE | Biocartis NV
PRESS RELEASE:  REGULATED INFORMATION 2 December 2022, 17:40 CET Disclosure of Outstanding Voting Securities Mechelen, Belgium, 2 December 2022 – Biocartis Group NV (the "Company" or "Biocartis"),...
Persbericht Biocartis Group NV: Openbaarmaking van uitstaande stemrechtverlenende effecten
02 déc. 2022 11h40 HE | Biocartis NV
PERSBERICHT: GEREGLEMENTEERDE INFORMATIE 2 december 2022, 17:40 CET Openbaarmaking van uitstaande stemrechtverlenende effecten Mechelen, België, 2 december 2022 – Biocartis Group NV...
AIMLogo.jpg
AIM ImmunoTech Announces Abstract Accepted for Poster Presentation at the British Society for Immunology Congress 2022
02 déc. 2022 10h45 HE | AIM ImmunoTech Inc.
OCALA, Fla., Dec. 02, 2022 (GLOBE NEWSWIRE) --  AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
Researchers from Insilico Medicine, University of Copenhagen, and University of Chicago unravel molecular secrets hidden in premature aging diseases and cancer using AI
01 déc. 2022 09h00 HE | InSilico Medicine
New York, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, and the University of Copenhagen announced...
Press release Biocartis Group NV: Disclosure of Outstanding Voting Securities
30 nov. 2022 01h00 HE | Biocartis NV
PRESS RELEASE: REGULATED INFORMATION30 November 2022, 07:00 CET Disclosure of Outstanding Voting Securities Mechelen, Belgium, 30 November 2022 – Biocartis Group NV (the "Company" or "Biocartis"),...